PRTA241220P7500
- 0.10
- 0.000.00%
Prothena Newsroom
Oppenheimer Maintains Prothena(PRTA.US) With Buy Rating, Maintains Target Price $62
Prothena Corp Analyst Ratings
RBC Capital Maintains Prothena(PRTA.US) With Hold Rating, Maintains Target Price $24
H.C. Wainwright Maintains Prothena(PRTA.US) With Buy Rating, Maintains Target Price $84
JMP Securities Maintains Prothena(PRTA.US) With Buy Rating, Maintains Target Price $83
Prothena's Strategic Advancements and Financial Strength Underpin Buy Rating
Oppenheimer Maintains Prothena(PRTA.US) With Buy Rating, Maintains Target Price $62
JMP Securities Maintains Prothena(PRTA.US) With Buy Rating, Maintains Target Price $83
H.C. Wainwright Maintains Prothena(PRTA.US) With Buy Rating, Maintains Target Price $84
A Quick Look at Today's Ratings for Prothena(PRTA.US), With a Forecast Between $24 to $84
Prothena Is Maintained at Neutral by B of A Securities
HC Wainwright & Co. Reiterates Buy on Prothena Corp, Maintains $84 Price Target
Prothena Buy Rating Affirmed: Leadership Changes and Prasinezumab's Promise Signal Investment Opportunity
Prothena Corp Analyst Ratings
Oppenheimer Maintains Prothena(PRTA.US) With Buy Rating, Maintains Target Price $62
Oppenheimer Keeps Their Buy Rating on Prothena (PRTA)
Prothena Corp Analyst Ratings
Oppenheimer Maintains Prothena(PRTA.US) With Buy Rating, Cuts Target Price to $62
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Prothena (PRTA) and Xenon (XENE)
RBC Capital Maintains Sector Perform on Prothena Corp, Lowers Price Target to $24